Mark Humayun: Most of the steps and procedures of Argus II implantation are familiar to vitreoretinal surgeons. However, some parts are new, and the combination of surgical steps is unique and somewhat complex. We’re very familiar with isolating the muscles, doing conjunctival peritomy, and putting scleral buckles underneath muscles and around the eye.
I am fortunate to have been helped by many along the way, and especially Second Sight Medical Products, as without a dedicated company focused on developing such an implant, it would have remained a research project.
ARGUS II Patient Lisa Kulik Regains Vision
Mark Humayun: We are exploring image-processing techniques such as zoom and finding that some patients with the Argus II are able to achieve 20/200 acuity. That’s a big jump from 20/1260 without zoom.
Envision, for example, that when you’re sitting at a table to see something fine, you can zoom in, and then when you’re walking, you can zoom back down to zero magnification. Those sorts of schemes will definitely come into play.
Second Sight Announces Expansion of Medicare …
The FDA’s Argus II approval drew worldwide media coverage. A number of stories highlighted the case of 61-year-old Kathy Blake, who is Dr. Humayun’s patient and the first RP patient in the US to be implanted with the device. The Argus II restored her sight after having been blind for 23 years. She was featured on NBC Nightly News with Brian Williams1 and on ABC Good Morning America.2
Second Sight Argus® II Retinal Prosthesis System …
Mark Humayun: It’s possible. The concern is, I think everybody wants to put these implants in; I’ve already had a lot of requests. But as mentioned, initially Argus II will be available at only a limited number of centers of excellence, so it doesn’t make sense to have a big wet lab and have everybody train up on it. For now, I think it’s wiser to focus on the centers that will offer Argus II in 2013 and get them up to speed.
Second Sight: Argus II Retinal Prosthesis System Review
Argus II has been FDA approved as a humanitarian-use device, an approval pathway limited to devices that treat or diagnose fewer than 4000 people in the US each year.
Second Sight FR 2012 Argus II Retinal Prosthesis …
The FDA requires that Argus II patients be willing and able to complete the recommended post-implant clinical follow-up, device fitting, and visual rehabilitation.
Second Sight Announces Market Entry into Iran with …
Lyndon da Cruz, MA, MD, PhD
• professor of stem cell and retinal transplantation surgery, University College London, and consultant ophthalmic surgeon specializing in medical and surgical retina at Moorfields Eye Hospital, both in London, UK
• financial disclosure: Second Sight provides institutional funding to Moorfields Eye Hospital for the trial of the Argus II retinal prosthesis system; however, the author has no financial interest in the sale of the device.
• +020 7566 2251;